Jade Biosciences Statistics
Total Valuation
JBIO has a market cap or net worth of $917.07 million. The enterprise value is $457.26 million.
| Market Cap | 917.07M |
| Enterprise Value | 457.26M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JBIO has 63.60 million shares outstanding.
| Current Share Class | 63.60M |
| Shares Outstanding | 63.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +5.67% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 97.69% |
| Float | 51.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.93, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.93 |
| Quick Ratio | 14.61 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.76 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -37.39% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.26M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, JBIO has paid $89,000 in taxes.
| Income Tax | 89,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +77.59% |
| 50-Day Moving Average | 20.06 |
| 200-Day Moving Average | 18.34 |
| Relative Strength Index (RSI) | 22.10 |
| Average Volume (20 Days) | 1,019,047 |
Short Selling Information
The latest short interest is 9.99 million, so 15.72% of the outstanding shares have been sold short.
| Short Interest | 9.99M |
| Short Previous Month | 9.65M |
| Short % of Shares Out | 15.72% |
| Short % of Float | 19.23% |
| Short Ratio (days to cover) | 12.92 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -164.74M |
| Pretax Income | -153.15M |
| Net Income | -124.44M |
| EBITDA | -164.70M |
| EBIT | -164.74M |
| Earnings Per Share (EPS) | -$2.34 |
Balance Sheet
The company has $461.21 million in cash and $1.39 million in debt, with a net cash position of $459.82 million or $7.23 per share.
| Cash & Cash Equivalents | 461.21M |
| Total Debt | 1.39M |
| Net Cash | 459.82M |
| Net Cash Per Share | $7.23 |
| Equity (Book Value) | 439.92M |
| Book Value Per Share | 6.92 |
| Working Capital | 439.68M |
Cash Flow
In the last 12 months, operating cash flow was -$123.51 million and capital expenditures -$60,000, giving a free cash flow of -$123.57 million.
| Operating Cash Flow | -123.51M |
| Capital Expenditures | -60,000 |
| Depreciation & Amortization | 39,000 |
| Net Borrowing | -205.00M |
| Free Cash Flow | -123.57M |
| FCF Per Share | -$1.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -13.57% |
| FCF Yield | -13.47% |
Analyst Forecast
The average price target for JBIO is $50.13, which is 247.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.13 |
| Price Target Difference | 247.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |